First-Line Treatment for Bacterial Vaginosis
For symptomatic bacterial vaginosis in adult women, treat with oral metronidazole 500 mg twice daily for 7 days. This is the most consistently recommended first-line regimen across CDC guidelines and has the highest cure rate at 95% 1.
Recommended First-Line Regimens
The CDC guidelines establish three equally acceptable first-line options 1:
- Oral metronidazole 500 mg twice daily for 7 days (preferred)
- Metronidazole gel 0.75%, one applicator (5g) intravaginally once daily for 5 days
- Clindamycin cream 2%, one applicator (5g) intravaginally at bedtime for 7 days
However, the oral metronidazole regimens are equally efficacious, while vaginal clindamycin cream appears less efficacious than metronidazole regimens 1. This makes oral metronidazole the superior choice when efficacy is prioritized.
Key Clinical Considerations
Patient Counseling
- Advise complete alcohol avoidance during metronidazole treatment and for 24 hours after completion to prevent disulfiram-like reactions 1
- Clindamycin cream is oil-based and weakens latex condoms and diaphragms 1
- Recurrence is common (50-80% within one year), and patients should return if symptoms recur 2
Alternative Regimens (Lower Efficacy)
Use only when first-line options are not tolerated 1:
- Metronidazole 2g orally single dose (84% cure rate vs 95% for 7-day regimen) 3
- Clindamycin 300 mg orally twice daily for 7 days
- Clindamycin ovules 100g intravaginally at bedtime for 3 days
Allergy or Intolerance
If metronidazole allergy or intolerance exists, use clindamycin cream or oral clindamycin 1. Do not use metronidazole gel in patients with true metronidazole allergy 1.
Special Populations
Pregnancy
All symptomatic pregnant women should be tested and treated due to associations with preterm birth, premature rupture of membranes, and postpartum endometritis 1, 4:
- Recommended: Metronidazole 250 mg orally three times daily for 7 days 1
- Alternative: Clindamycin 300 mg orally twice daily for 7 days
Avoid topical clindamycin cream in pregnancy - three trials showed increased adverse events including prematurity and neonatal infections 1. Multiple studies confirm no teratogenic or mutagenic effects from metronidazole use in pregnancy 1.
High-risk pregnant women (prior preterm delivery) with asymptomatic BV should be screened and treated in early second trimester 1, 4.
Recurrent BV
Recent breakthrough evidence shows that treating male partners significantly reduces recurrence 5. In the 2025 StepUp trial, partner treatment (oral metronidazole 400mg + topical 2% clindamycin cream, both twice daily for 7 days) reduced recurrence from 63% to 35% at 12 weeks (P<0.001) 5. This represents a paradigm shift in BV management 6, 7.
For recurrent cases without partner treatment:
- Use longer courses of first-line therapy 8
- Consider vaginal boric acid as alternative 9
- Vaginal Lactobacillus crispatus products show promise 9, 2
Management Pearls
Partner Treatment
Routine partner treatment was historically not recommended 1, but this has changed. The 2025 StepUp trial provides Level I evidence that partner treatment prevents recurrence 5, and recent ACOG guidelines now recommend partner therapy for recurrent BV 6.
Follow-Up
- No follow-up needed if symptoms resolve 1
- Exception: High-risk pregnant women should have follow-up at 1 month to confirm cure 4
Pre-Procedural Treatment
Screen and treat BV before surgical abortion or hysterectomy to reduce postoperative infectious complications (10-75% reduction in complications) 1. Treatment substantially reduces post-abortion PID 3.
Common Pitfalls to Avoid
- Do not use single-dose metronidazole 2g as first-line - cure rate only 84% vs 95% for 7-day regimen 3
- Do not treat asymptomatic non-pregnant women unless undergoing invasive procedures 3
- Do not use topical clindamycin in pregnancy due to adverse neonatal outcomes 1
- Do not ignore partner treatment in recurrent cases - new evidence strongly supports this approach 5, 6
- Probiotics and douching are not recommended - insufficient evidence 1